TAIPEI MEDICAL UNIVERSITY FOUNDATION*TMU

Their core work

Taipei Medical University (TMU) is a Taiwan-based medical teaching and research university with affiliated hospitals, active in clinical medicine, biomedical research, and public health. In H2020 it joined European consortia as a non-EU partner contributing clinical expertise, access to Asian patient cohorts, and health data analytics to projects on smoking prevention, public health policy, and AI-based personalised health monitoring. Their value to European partners is an Asia-Pacific clinical and epidemiological perspective, particularly on cancer and non-communicable disease research.

What they specialise in

How they've shifted over time

In the first half of their H2020 track (2015-2018) TMU worked on behavioural prevention and population-level public health, through SmokeFreeBrain and the launch of CrowdHEALTH. In the second half (2019-2024) the focus shifts clearly toward AI-driven clinical decision support, personalised monitoring, and cancer research under iHELP. The trajectory moves from public-health prevention campaigns toward individualised, data-driven clinical care powered by machine learning.

TMU is moving from population-level prevention studies toward AI and decision-support tools for personalised medicine, making them a relevant partner for future clinical-AI and oncology data collaborations.

How they like to work

TMU consistently joins large European consortia as a participant rather than coordinator, contributing as a non-EU clinical partner on Research and Innovation Actions. Across three projects they worked with 45 distinct partners in 13 countries, indicating a hub-style network with broad reach rather than a repeat circle of collaborators. They are comfortable in large, multidisciplinary teams where clinical validation and Asian patient data are needed.

Collaborated with 45 unique partners across 13 countries over three projects, spanning European health research consortia and bringing in an Asia-Pacific node. No single country dominates — their network is diffuse across the EU with Taiwan as an extra-European anchor.

What sets them apart

TMU is one of the few Taiwan-based universities consistently embedded in H2020 health consortia, giving European partners direct access to Asian clinical populations, hospital networks, and regulatory context. Unlike many EU medical schools, they bridge a different healthcare system and epidemiological profile, which is particularly valuable for cancer and non-communicable disease studies. They are a consistent participant across three sequential health projects spanning 2015-2024, showing durable engagement rather than a one-off collaboration.

Highlights from their portfolio

• iHELP
  Their most recent and forward-looking project, combining AI, personalised monitoring, and cancer research — reflecting where TMU is heading.
• CrowdHEALTH
  Positioned TMU inside European public health policy research, using collective health data to inform decision-making across countries.
• SmokeFreeBrain
  Their entry project into H2020, focused on multidisciplinary smoking prevention — a clear behavioural and public-health contribution.